相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid
Isabel V. L. Wilkinson et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid
Maria Chatzopoulou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
Simon Guiraud et al.
HUMAN MOLECULAR GENETICS (2019)
Development of Novel Micro-dystrophins with Enhanced Functionality
Julian N. Ramos et al.
MOLECULAR THERAPY (2019)
Micro-dystrophin Genes Bring Hope of an Effective Therapy for Duchenne Muscular Dystrophy
Kay E. Davies et al.
MOLECULAR THERAPY (2019)
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
Christopher E. Nelson et al.
NATURE MEDICINE (2019)
Membrane recruitment of nNOSμ, in microdystrophin gene transfer to enhance durability
Jessica F. Boehler et al.
NEUROMUSCULAR DISORDERS (2019)
Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models
Yafeng Song et al.
NATURE MEDICINE (2019)
CRISPR Correction of Duchenne Muscular Dystrophy
Yi-Li Min et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
Simon Guiraud et al.
HUMAN MOLECULAR GENETICS (2019)
Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
Michael J. Gait et al.
NUCLEIC ACID THERAPEUTICS (2019)
Blocking tumor-associated immune suppression with BAY-218, a novel, selective aryl hydrocarbon receptor (AhR) inhibitor
Ilona Gutcher et al.
CANCER RESEARCH (2019)
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet
Francesco Muntoni et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
Yuko Shimizu-Motohashi et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy
Akinori Nakamura
JOURNAL OF PERSONALIZED MEDICINE (2019)
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Dongsheng Duan
MOLECULAR THERAPY (2018)
The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
Simon Guiraud et al.
EXPERT OPINION ON ORPHAN DRUGS (2018)
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
Kenji Rowel Q. Lim et al.
JOURNAL OF PERSONALIZED MEDICINE (2018)
Progress toward Gene Therapy for Duchenne Muscular Dystrophy
Joel R. Chamberlain et al.
MOLECULAR THERAPY (2017)
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Caroline Le Guiner et al.
NATURE COMMUNICATIONS (2017)
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Pharmacological advances for treatment in Duchenne muscular dystrophy
Simon Guiraud et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single-and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy
Valeria Ricotti et al.
PLOS ONE (2016)
New Trends in Aryl Hydrocarbon Receptor Biology
Sonia Mulero-Navarro et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
The Pathogenesis and Therapy of Muscular Dystrophies
Simon Guiraud et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 16 (2015)
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy
Simon Guiraud et al.
EXPERIMENTAL PHYSIOLOGY (2015)
How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse
Caroline Godfrey et al.
HUMAN MOLECULAR GENETICS (2015)
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Catherine L. Bladen et al.
HUMAN MUTATION (2015)
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, Following Single-and Multiple-Dose Administration to Healthy Male Adult Volunteers
Jon Tinsley et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Microtubule binding distinguishes dystrophin from utrophin
Joseph J. Belanto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research
Nam Trung Nguyen et al.
FRONTIERS IN IMMUNOLOGY (2014)
Identification of a High-Affinity Ligand That Exhibits Complete Aryl Hydrocarbon Receptor Antagonism
Kayla J. Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Identification of the Aryl Hydrocarbon Receptor Target Gene TiPARP as a Mediator of Suppression of Hepatic Gluconeogenesis by 2,3,7,8-Tetrachlorodibenzo-p-dioxin and of Nicotinamide as a Corrective Agent for This Effect
Silvia Diani-Moore et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Marginal Level Dystrophin Expression Improves Clinical Outcome in a Strain of Dystrophin/Utrophin Double Knockout Mice
Dejia Li et al.
PLOS ONE (2010)
Ah receptor represses acute-phase response gene expression without binding to its cognate response element
Rushang D. Patel et al.
LABORATORY INVESTIGATION (2009)
Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1α, drives utrophin gene expression at the neuromuscular junction
LM Angus et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
Function and genetics of dystrophin and dystrophin-related proteins in muscle
DJ Blake et al.
PHYSIOLOGICAL REVIEWS (2002)
分享论文
